Editorial Staff

Valuing Life-Saving Drugs: What is the Price of Life and Who Decides?

/in , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Hubwonk host Joe Selvaggi talks with Pioneer Institute visiting fellow Dr. Bill Smith about Quality Adjusted Life Years (QALY) standards, and the ways in which so-called objective cost-containing strategies use expert opinion to determine the value of a life and thereby disadvantage the elderly, disabled, and those with less common vulnerabilities to disease.

Guest:

William S. Smith is Visiting Fellow in Life Sciences at Pioneer Institute. He has 25 years of experience in government and in corporate roles, including as vice president of public affairs and policy at Pfizer, and as a consultant to major pharmaceutical, biotechnology and medical device companies. He held senior staff positions for the Republican House leadership on Capitol Hill, the White House, and in the Massachusetts Governor’s office. He is affiliated as research fellow and managing director with the Center for the Study of Statesmanship at The Catholic University of America (CUA), where he earned his PhD.

Related research: Analysis: ICER Framework Ignores Patient Preferences, Innovation & Societal Benefits in Evaluating Cost-Effectiveness of New Cancer Treatments

Get new episodes of Hubwonk in your inbox!

Related Posts:

Hubwonk Ep. 5: COVID Calling: How answering the tracing phone call will move us forward

0 Comments
/
In this episode, Host Joe Selvaggi and Co-Host Barbara Anthony speak with the heads of Partners in Health Drs. Sheila Davis & John Welch on how they are bringing their expertise battling Ebola in West Africa to defeating the COVID-19 epidemic in Massachusetts. They explore precisely how and why tracing is an essential element in battling the epidemic.

Conquering COVID-19: When and From Where Will Vaccines and Therapies Emerge?

0 Comments
/
This week on Hubwonk, Host Joe Selvaggi is joined by Pioneer’s Bill Smith, Visiting Fellow in Life Sciences, and Dr. Peter Kolchinsky, Harvard-trained virologist, biotech investor and author of the new book, The Great American Drug Deal, to learn how the SARS-CoV2 works, what a vaccine may look like, and how we might produce it to scale.

A Tipping Point for Telehealth – Bringing Healthcare into Your Home

0 Comments
/
This week on "Hubwonk," Joe Selvaggi and Josh Archambault talk with Dr. Roy Schoenberg, Chief Executive of Amwell, a global telehealth technology company headquartered in Boston, about the promise of telemedicine and how the COVID-19 pandemic has catalyzed broader adoption.

Coronavirus & Contracts – Protecting Massachusetts Attorneys & Clients from Risk

0 Comments
/
In this episode of "Hubwonk," host Joe Selvaggi and Pioneer’s Chief Financial Officer & Director of Government Transparency, Mary Connaughton, speak with attorney and entrepreneur Kosta Ligris about how Massachusetts’ requirement for live attestation for many vital contracts is putting attorneys and clients at risk of exposure to coronavirus.

Buoy Health – Intelligent Front Door to Optimized Healthcare

0 Comments
/
In this first episode of Pioneer's new podcast, Hubwonk, host Joe Selvaggi and Pioneer Senior Fellow in Healthcare Josh Archambault talk with Dr. Andrew Le, cofounder and Chief Executive Officer of Buoy Health.

Pioneer Institute Launches Its New Policy Podcast, “HubWonk”

Pioneer Institute is pleased to announce the launch today of a new, weekly podcast called “HubWonk,” covering timely topics, with insights and in-depth interviews on the issues that affect our quality of life, ability to prosper, and liberties. 

New Report: Quality Adjusted Life Years (QALY) Methodology Discriminates Against Older Americans, Threatens to Deny Seniors Access to Life-Saving Care

New report asserts that with older americans more vulnerable during the COVID-19 pandemic, all health plans should avoid using the QALY methodology when assessing the value of care for older patients
A Woman Helping a Disabled Man in a Wheelchair

New Report & Legal Analysis Suggests ICER’s Quality Adjusted Life Years Methodology Violates the Americans with Disabilities Act

A new report, "The Legality of QALY under the ADA," outlines several potential legal violations and negative implications for disabled individuals related to the adoption of the QALY approach to drug value assessment, used most prominently by ICER.

Study Urges Caution Before Adopting ICER Reviews to Determine Cost Effectiveness of Treatments

Review methodology could negatively impact elderly, the disabled,…